skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Novel research translates to clinical cases of schizophrenic and cocaine psychosis

(1878) Views  (501) Full article downloads

Authors: João V Nunes, Patricia A Broderick

Published Date May 2007 Volume 2007:3(4) Pages 475 - 485
DOI: http://dx.doi.org/10.2147/NDT.S

João V Nunes1, Patricia A Broderick2,3

1Department of Behavioral Medicine, The City University of New York Medical School, The Sophie Davis School of Biomedical Education, NY, NY, USA; 2Department of Physiology and Pharmacology, The City University of New York Medical School, The Sophie Davis School of Biomedical Education, NY, NY, USA; 3Department of Neurology, New York University (NYU) School of Medicine, NYU Comprehensive Epilepsy Center, NY, NY, USA

Abstract: Pharmacotherapies for schizophrenic and cocaine psychoses are complex but similar because of similarities in their brain neurochemistry and behavioral outcomes. Their neurochemical neuronal mechanisms of action, as shown in preclinical and clinical studies, involve primarily dopaminergic dysfunction and, secondarily, neuroadaptive effects that seem to involve central serotonergic function. Behavioral outcomes of both disorders include hyperactivity and antipsychotic medications can ameliorate psychotic symptoms. Patients with both disorders often arrive at emergency departments and present floridly psychotic with a predominance of positive symptoms, often prompting physicians to select a typical antipsychotic medication such as haloperidol. While this has become conventional wisdom, we believe that to use an atypical antipsychotic medication, such as risperidone, in the treatment of both psychoses is quite rational for long-term management of both positive and negative symptoms. Also, controlled clinical studies have shown that risperidone, an atypical antipsychotic medication, is successful in the treatment of cocaine dependence and withdrawal (Smelson et al 1997, 2002; Grabowski et al 2000). Furthermore, the availability and effectiveness of long-acting risperidone in injectable form opens new possibilities for the long-term management of both disorders. In this paper, we present data which show that the use of risperidone is plausible for effective pharmacotherapy of schizophrenic and cocaine psychoses.

Keywords: schizophrenia, cocaine psychosis, psychopharmacotherapy, typical antipsychotic, atypical antipsychotic, risperidone








Readers of this article also read:

The clinical differentiation of fronto-temporal dementia from psychiatric disease
Ziprasidone in the treatment of mania in bipolar disorder
Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies
Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature
Excited delirium: Consideration of selected medical and psychiatric issues
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
Hyperbaric oxygen ameliorates worsening signs and symptoms of post-traumatic stress disorder
Moderate alcohol consumption and cognitive risk
The GENACIS project: a review of findings and some implications for global needs in women-focused substance abuse prevention and intervention